SCHEDULE 13G: L1 Capital Global Opportunities Master Fund Discloses Significant Stake in Aptevo Therapeutics

L1 Capital Global Opportunities Master Fund, Ltd. has disclosed a 9.95% beneficial ownership stake in Aptevo Therapeutics Inc., primarily through common stock holdings.

Summary

• L1 Capital Global Opportunities Master Fund, Ltd. has filed a Schedule 13G, reporting beneficial ownership in Aptevo Therapeutics Inc.
• The fund beneficially owns 285,000 shares of Aptevo Therapeutics Inc. Common Stock.
• This ownership represents 9.95% of the class of securities, based on 2,864,156 Common Stock outstanding immediately after a recent offering.
• The reported beneficial ownership includes sole voting power and sole dispositive power over the 285,000 shares.
• The fund also holds 1,489,375 Warrants, 12,875 Pre-funded Warrants, and 20,000 Warrants purchased on April 25, 2025, which are subject to a 4.99% beneficial ownership limitation and are not included in the 9.95% reported stake.
• The acquisition of these securities was not for the purpose of changing or influencing the control of Aptevo Therapeutics Inc.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of beneficial ownership. While the acquisition of a significant stake by an institutional investor can be seen as a positive signal, the filing itself is neutral in tone and does not contain performance-related information.

Positives

• The disclosure of a significant 9.95% stake by an institutional investor like L1 Capital Global Opportunities Master Fund, Ltd. can be interpreted as a vote of confidence in Aptevo Therapeutics Inc.'s future prospects.
• The investment is passive, indicating the fund is not seeking to influence control, which can provide stability.

Negatives

• The filing itself does not contain any negative information regarding Aptevo Therapeutics Inc.'s operations or financial performance.

Risks

• The document does not explicitly mention specific risks related to Aptevo Therapeutics Inc.'s operations or financial health, as it is a beneficial ownership filing.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Aptevo Therapeutics Inc.'s future operations or financial performance, as it is a beneficial ownership disclosure.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This Schedule 13G filing indicates a significant passive investment by an institutional fund in a biotechnology company. Such disclosures are common in the financial markets and provide transparency regarding large ownership stakes, which can signal investor confidence or strategic positioning within a sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor can influence market perception and potentially the stock price, signaling increased institutional interest in Aptevo Therapeutics Inc.

Key Dates

Keywords

Aptevo Therapeutics, L1 Capital Global Opportunities Master Fund, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, SEC Filing, Equity Stake, Warrants